COMPANY
Clinical Phase 1
Keywords: antibody-drug conjugate ADC oncology cancer Locally Advanced (Unresectable) or Metastatic Solid Tumors NEOK001 NEOK002
Location: Palo Alto, CA · source · Oct 15, 2026
Profile checked Oct 10, 2026
Timeline
- Trial start Phase 1: A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors source ↗
- Trial start Phase 1: A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors source ↗
Upcoming milestones
- 2029-01 (ESTIMATED) · Phase 1 · A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors · NCT07612176
- 2029-02 (ESTIMATED) · Phase 1 · A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors · NCT07612189
Estimated primary completion per ClinicalTrials.gov. Dates move.
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT07612176 | A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors | Phase 1 | Recruiting | Apr 21, 2026 | 2029-01 (estimated) |
| NCT07612189 | A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors | Phase 1 | Recruiting | Apr 22, 2026 | 2029-02 (estimated) |
